Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $25.5714.

A number of equities analysts have recently issued reports on the stock. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 18th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Wedbush increased their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the sale, the insider owned 18,469 shares of the company’s stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the business’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the sale, the director directly owned 91,585 shares in the company, valued at $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 107,719 shares of company stock valued at $2,063,359 in the last 90 days. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after acquiring an additional 5,084 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth $72,000. Finally, US Bancorp DE lifted its holdings in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares during the last quarter.

Stoke Therapeutics Trading Down 1.8%

Shares of Stoke Therapeutics stock opened at $23.46 on Friday. The business has a 50-day moving average price of $16.05 and a two-hundred day moving average price of $11.52. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $24.60. The company has a market cap of $1.29 billion, a P/E ratio of 27.60 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Equities research analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.